SCHEMBL5457944

SCHEMBL5457944

N#CC(=Cc1ccco1)C(=O)Nc1sc2c(c1C(N)=O)CCCC2

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 8/20 0.69
▸ FLT3 P36888 6/20 0.65
▸ NPC1 O15118 6/20 0.57
▸ RAB9A P51151 6/20 0.57
▸ ALDH1A1 P00352 6/20 0.57
▸ SMN1; SMN2 Q16637 4/20 0.57
▸ HPGD P15428 2/20 0.57
▸ LMNA P02545 5/20 0.52
▸ MEN1 O00255 4/20 0.52
▸ KMT2A Q03164 4/20 0.52
▸ KDM4E B2RXH2 3/20 0.52
▸ POLB P06746 2/20 0.52
▸ NR0B1 P51843 1/20 0.52
▸ L3MBTL1 Q9Y468 4/20 0.51
▸ TSHR P16473 2/20 0.51
▸ TDP1 Q9NUW8 2/20 0.51
▸ GFER P55789 1/20 0.51
▸ HTT P42858 1/20 0.51
▸ RECQL P46063 1/20 0.51
▸ HSD17B10 Q99714 2/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3923490 0.79 FLT3 (1.00) MAPTFLT3NPC1RAB9AALDH1A1
SCHEMBL3923491 0.79 FLT3 (1.00) MAPTFLT3NPC1RAB9AALDH1A1
SCHEMBL5453296 0.75 FLT3 (1.00) MAPTFLT3NPC1RAB9AALDH1A1
SCHEMBL8290734 0.73 HPGD (1.00) MAPTFLT3NPC1RAB9AALDH1A1
SCHEMBL11485439 0.70 PTPN1 (0.78) MAPTFLT3NPC1RAB9AALDH1A1
SCHEMBL5451249 0.70 RAB9A (0.72) MAPTFLT3NPC1RAB9AALDH1A1
SCHEMBL5451052 0.68 ALDH1A1 (1.00) MAPTFLT3RAB9AALDH1A1SMN1; SMN2
SCHEMBL8288675 0.68 FLT3 (0.74) MAPTFLT3NPC1RAB9AALDH1A1
SCHEMBL3128198 0.68 FLT3 (1.00) MAPTFLT3NPC1RAB9AALDH1A1
SCHEMBL8289499 0.67 ALDH1A1 (0.73) MAPTFLT3RAB9AALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents GPC BIOTECH AG (DE) 2007-11-29 — — US claimed
EP-1670804-A2 HETEROBICYCLIC COMPOUNDS AS PHARMACEUTICALLY ACTIVE AGENTS GPC Biotech AG (DE) 2006-06-21 — — EP claimed
WO-2005023818-A2 HETEROBICYCLIC COMPOUNDS AS PHARMACEUTICALLY ACTIVE AGENTS GPC BIOTECH AG (DE) 2005-03-17 — — WO claimed
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents GPC BIOTECH AG (DE) 2007-11-29 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents TBCA, PARK7, NFATC1 MAPT 21/4885FLT3 3509/4885NPC1 2627/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback